Genenta Science S.p.A.

NasdaqCM:GNTA Stock Report

Market Cap: US$91.8m

Genenta Science Valuation

Is GNTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GNTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GNTA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GNTA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GNTA?

Key metric: As GNTA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for GNTA. This is calculated by dividing GNTA's market cap by their current book value.
What is GNTA's PB Ratio?
PB Ratio5.2x
Book€16.82m
Market Cap€87.22m

Price to Book Ratio vs Peers

How does GNTA's PB Ratio compare to its peers?

The above table shows the PB ratio for GNTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.1x
MNOV MediciNova
1.6x-6.1%US$89.8m
CRVO CervoMed
1.9x-46.1%US$88.9m
CUE Cue Biopharma
3x-3.9%US$75.0m
CASI CASI Pharmaceuticals
5.8x9.0%US$80.2m
GNTA Genenta Science
5.2x56.8%US$91.8m

Price-To-Book vs Peers: GNTA is expensive based on its Price-To-Book Ratio (5.2x) compared to the peer average (3.1x).

Price to Book Ratio vs Industry

How does GNTA's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$497.29m
AMRN Amarin
0.4x-7.7%US$205.67m
IMAB I-Mab
0.4x1.8%US$84.69m
ACET Adicet Bio
0.4x6.7%US$78.03m
GNTA 5.2xIndustry Avg. 1.9xNo. of Companies77PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: GNTA is expensive based on its Price-To-Book Ratio (5.2x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is GNTA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GNTA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GNTA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GNTA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.02
US$22.98
+357.7%
8.6%US$24.95US$21.01n/a2
Nov ’25US$5.45
US$22.98
+321.6%
8.6%US$24.95US$21.01n/a2
Sep ’25US$3.87
US$23.01
+494.7%
8.7%US$25.01US$21.02n/a2
Aug ’25US$4.43
US$23.01
+419.5%
8.7%US$25.01US$21.02n/a2
Jul ’25US$3.08
US$23.01
+646.5%
8.7%US$25.01US$21.02n/a2
Jun ’25US$3.19
US$23.01
+621.4%
8.7%US$25.01US$21.02n/a2
May ’25US$3.29
US$23.02
+600.9%
8.7%US$25.03US$21.02n/a2
Apr ’25US$3.61
US$23.02
+537.8%
8.7%US$25.03US$21.02n/a2
Mar ’25US$4.19
US$23.02
+449.5%
8.7%US$25.03US$21.02n/a2
Oct ’24US$5.15
US$23.21
+350.7%
6.9%US$24.82US$21.60US$4.082
Sep ’24US$5.51
US$23.21
+321.3%
6.9%US$24.82US$21.60US$3.872
Aug ’24US$5.38
US$19.22
+257.0%
22.8%US$25.08US$14.97US$4.434
Jul ’24US$5.89
US$18.96
+221.7%
22.4%US$24.60US$14.76US$3.084
Jun ’24US$5.51
US$20.60
+273.9%
20.3%US$24.97US$14.98US$3.193
May ’24US$6.16
US$20.60
+234.6%
20.3%US$24.97US$14.98US$3.293
Apr ’24US$5.75
US$20.70
+260.0%
19.8%US$25.28US$15.34US$3.613
Mar ’24US$6.35
US$21.25
+234.7%
17.9%US$24.97US$15.15US$4.194
Feb ’24US$6.00
US$21.88
+264.7%
19.5%US$26.58US$15.00US$3.964
Jan ’24US$5.50
US$22.71
+313.0%
7.4%US$24.98US$20.98US$4.953
Dec ’23US$5.25
US$22.71
+332.6%
7.4%US$24.98US$20.98US$5.243
Nov ’23US$4.60
US$22.71
+393.6%
7.4%US$24.98US$20.98US$5.343

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.43

7D

-5.4%

1Y

73.9%

IQVIA Holdings

US$35.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$192.68

7D

-11.2%

1Y

-6.1%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.58

7D

-8.4%

1Y

10.3%